Skip to the content

Dr Barbara Kemp-Harper

Dr Barbara Kemp-Harper

Current Position

Research Fellow


Department of Pharmacology
Monash University
Clayton, Victoria, 3800  Australia

Phone:  +61 3 9905 4674
Facsimile:  +61 3 9902 9500

Dr Barbara Kemp-Harper obtained her Ph.D in 1995 under the supervision of Dr Tom Cocks and Dr Joe Smolich at the Baker Institute and the Department of Pharmacology, University of Melbourne.  Her studies focused on the role of the endothelium in the control of pulmonary vascular function. In 1998 she was awarded an NHMRC CJ Martin Fellowship to conduct postdoctoral studies at the Wolfson Institute for Biomedical Research, London with Professor Salvador Moncada.  Here she pursued her interests in nitric oxide signalling and studied its ability to regulate mitochondrial respiration.

In 2000 she returned to the Department of Pharmacology at Monash University where she established her own Vascular Pharmacology Group.  In 2001 she instigated a research program examining the vasoprotective actions of nitroxyl, a novel redox sibling of nitric oxide.  In 2008 she was awarded a Foundation for High Blood Pressure Research Postdoctoral Fellowship and she and her research team joined the Vascular Biology and Immunopharmacology Group, co-lead by Chris Sobey and Grant Drummond.

She is currently a Chief Investigator on 3 NHMRC Project Grants, an ASCEPT Councillor and a Guest Editor for a Forum Issue on HNO in Antioxidants & Redox Signaling. Her research aims to identify novel strategies for the prevention and treatment of vascular disease with a focus on the HNO/NO/sGC signalling pathway.

Barb’s work has examined the role of nitric oxide and its novel redox form, nitroxyl in the regulation of vascular function in the setting of health and disease.  She has shown that nitroxyl donors have distinct pharmacological actions and therapeutic advantages over nitric oxide donors in the treatment of vascular dysfunction associated with hypertension and atherosclerosis.  She has identified nitroxyl as an endogenous regulator of vascular tone and her research is currently investigating the ability of novel nitric oxide mimetics to confer protection in the setting of hypertension and stroke.

Journal Publications (since 2005)

Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, Horowitz JD, Kemp-Harper BK (2009). Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO and beyond. Pharmacology & Therapeutics 124(3):279-300

Favaloro JL, Kemp-Harper BK (2009). Redox variants of nitric oxide (NO• and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms Am J Physiol 295(5):H1274-1280 

Andrews KL, Irvine JC, Tare M, Aposolopoulos J, Favaloro J, Triggle CR, Kemp-Harper BK (2009). A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarising factor in resistance arteries. Br J Pharmacol 157(4):540-550

Kemp-Harper BK, Schmidt HHHW (2009). cGMP in the vasculature. Handb Exp Pharmacol 191:447-467.

Irvine JC, Ritchie RH, Favaloro JL, Andrews KL, Widdop RE, Kemp-Harper BK (2008). Nitroxyl (HNO): the Cinderella of the nitric oxide story. Trends Pharmacol Sci 29(12):601-608.

Kirsch M, Kemp-Harper B, Weissmann N, Grimminger F, Schmidt HH (2008). Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling. FASEB J 22(1):30-40.

Kemp-Harper B, Feil R (2008) Meeting report: cGMP matters. Sci Signal 1(9):pe12.

Favaloro JL, Kemp-Harper BK (2007). The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. Cardiovasc. Res., 73, 587-596.

Irvine JC, Favaloro JL, Widdop RE, Kemp-Harper BK (2007). Nitroxyl anion (HNO) donor, Angeli’s salt, does not develop tolerance in rat isolated aortae. Hypertension, 49, 1-8.

Selemidis S, Dusting GJ, Peshavariya H, Kemp-Harper BK, Drummond GR (2007). Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc Res 75(2):349-58.

Fitzgerald SM, Kemp-Harper BK, Parkington HC, Head GA, Evans RG (2007). Endothelial dysfunction and arterial pressure regulation during early diabetes in mice: roles for nitric oxide and endothelium-derived hyperpolarizing factor. Am J Physiol 293(2):R707-13.

Villar IC, Panayiotou CM, Sheraz A, Madhani M, Scotland RS, Nobles M, Kemp-Harper BK, Ahluwalia A, Hobbs AJ (2007). Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarizing factor. Cardiovasc Res 74(3):515-25.

Stasch J-P, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Kumar A, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper BK, Muller-Esterl W, Schmidt HHHW (2006). Targeting the heme-oxidised nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest, 116(9), 2552-2561.

Feil R, Kemp-Harper BK (2006). cGMP signalling: from bench to bedside. EMBO Reports 7, 149-53.

Fitzgerald SM, Kemp-Harper BK, Tare M, Parkington HC (2005). Role of EDHF in endothelial dysfunction during diabetes. Clin Exp Pharmacol Physiol 32, 482-7.